{"nctId":"NCT00314249","briefTitle":"Study of Milnacipran for the Treatment of Fibromyalgia","startDateStruct":{"date":"2006-04"},"conditions":["Fibromyalgia"],"count":1025,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Milnacipran","type":"EXPERIMENTAL","interventionNames":["Drug: Milnacipran 100mg"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Milnacipran 100mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) Criteria\n\nExclusion Criteria:\n\n* psychiatric illness,\n* depression,\n* suicidal risk,\n* substance abuse,\n* pulmonary dysfunction,\n* renal impairment,\n* active cardiac disease,\n* liver disease,\n* autoimmune disease,\n* cancer,\n* inflammatory bowel disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Time-Weighted Average of Patient Experience Diary (PED) Reported Morning 24-Hour Recall Pain Scores for Weeks 1-12 of the Stable Dose Phase","description":"Time-weighted average (area under the curve \\[AUC\\]) of the weekly average Patient Experience Diary (PED)-reported morning recall pain scores for weeks 1 through 12 of the stable dose treatment phase is the area under the Patient Experience Diary (PED)-time curve estimated using the trapezoidal method and normalized by time.\n\nPED is the Patient Experience Diary, an electronic diary system used for collection of patient self-reported pain data. Outcome measure is assessed using the VAS Pain Intensity Scale from 0-100 millimeters anchored at 0 mm (no pain) to 100 mm (worst possible pain).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":"0.83"},{"groupId":"OG001","value":"41.2","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average of Patient Global Impression of Change (PGIC) From Visit TX0-TX12.","description":"Time-weighted average (area under the curve \\[AUC\\]) for Patient Global Impression of Change (PGIC) from Visit TX0-TX12 is the area under the PGIC-time curve estimated using the trapezoidal method and normalized by time.\n\nPGIC is an efficacy assessment on a scale of 1-7 taken at visits TX0-TX12. The wording of the assessment is as follows: \"Since the start of the study, overall my fibromyalgia is:\" 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No Change, 5=Minimally Worse, 6=Much Worse, and 7-Very Much Worse.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.06"},{"groupId":"OG001","value":"2.9","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Multi-Dimensional Fatigue Inventory (MFI) Total Score at Visit TX12.","description":"Change from Baseline in the Multi-Dimensional Fatigue Inventory (MFI) total score at TX12. Negative differences indicate decrease of fatigue.\n\nMFI is a subjective report of fatigue symptoms consisting of 20 items that can be scored to produce 5 dimensions: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. The MFI is a 1-5 scale with 1=\"yes, that is true\" and 5=\"no, that is not true.\"","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.96","spread":"0.549"},{"groupId":"OG001","value":"-5.50","spread":"0.599"}]}]}]},{"type":"PRIMARY","title":"Composite Syndrome Responder Status","description":"Composite Syndrome Responder Status is the number of responders based on 3 domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary \\[PED\\], electronic diary, during the morning report; 24 hour recall); (2) patient global impression of change (PGIC) score of \"very much improved\" and \"much improved;\" and (3) physical function improvement of 6 or more points on Short Form-36 Physical Component Summary (SF-36 PCS)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]},{"type":"PRIMARY","title":"Composite Pain Responder Status","description":"Composite Pain Responder Status is the number of responders based on two domains: (1) 30% reduction in pain (as recorded in the Patient Experience Diary \\[PED\\], electronic diary, during the morning report; 24 hour recall); and (2) Patient Global Impression of Change (PGIC) score of \"very much improved\" or \"much improved.\"","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average of the Short Form-36 Physical Component Summary (SF-36 PCS) Score From Visit TX0-TX12","description":"Short Form-36 (SF-36): pt. questionnaire (36 questions) which give rise to 8 domains \\& 2 component summaries (mental and physical); assessing quality of life, health \\& functional status.\n\nSF-36 PCS: weighted summary of physical function using all 8 domains.\n\nScores are standardized so that the range for all domains and component summaries is 0 (worst possible score) to 100 (best possible score). Higher scores indicate better health or functional status.\n\nSF-36 PCS AUC (Area under the Curve): estimated using trapezoidal method, normalized by time.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":"0.37"},{"groupId":"OG001","value":"37.9","spread":"0.37"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":509},"commonTop":["Nausea","Headache","Constipation","Insomnia","Dizziness"]}}}